Endocrine Abstracts

Background: Currently, there is no satisfying treatment option other than gross total or subtotal resection in combination with adjuvant radiotherapy for the treatment of craniopharyngiomas. However, recurrence could occur in a substantial proportion of craniopharyngiomas despite gross total resection and radiotherapy. Human epidermal growth factor receptor 2 (HER-2/ErbB2) overexpression was determined in various human carcinomas and is associated with aggressive clinical beha...

Background: Currently, multiple treatment options are available for the treatment of acromegaly. However, cure is obtained only in 50% of patients with macroadenomas after surgery. Persistent tumor enlargement occur in 2.2% of the patients treated with somatostatin analogs and in 1.6–2.9% of the patients treated with pegvisomant. The nuclear antigen Ki-67 is related to growth potential and is also a major prognostic indicator for pituitary adenomas. Studies demonstrated t...

Background: Currently, no effective medical treatment exists for recurrent and aggressive craniopharyngiomas that are resistant to conventional therapies, including repeat surgeries and adjuvant radiotherapy (RT). Temozolomide is an alkylating chemotherapeutic agent and is used routinely in the management of high grade gliomas. The response to temozolomide is suggested to be dependent on the tumoral expression of O-6 methylguanine DNA methyltransferase (MGMT). Evidence ...